Trial Profile
A Phase II Study of Apatinib In Combination With paclitaxel/platinum sequential treatment of advanced recrudescent Metastatic ovarian cancer
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 23 Jan 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 23 Jan 2017 New trial record